Limited Liability Company «Innovative Pharmacology Research» («IPHAR Co.» Ltd.)

Innovative Pharmacological Developments LLC (Iphar) is the leading organization in a group of companies developing medicines. The company was founded in 2004 with the support of the Foundation for the Promotion of the Development of Small Forms of Enterprises in the Scientific and Technical Field (Bortnik Fund), as an enterprise for the development of medicines.

Since 2009, Iphar has been included by the Russian Ministry of Health on the federal list of organizations and institutions conducting preclinical studies of drugs. In 2012, the company became a member of the Skolkovo project and became part of the organizations of the innovative territorial cluster “Pharmaceuticals, medical equipment and information technologies”.

In 2013, Iphar was granted the status of the Skolkovo Technopark Accredited Collective Use Center for Drug Development. In total, from 2007 to 2015, 18 spin-off companies were created that implement projects to develop innovative drugs (they are protected by patents in Russia, the CIS countries, the EU, and the USA). Today, the company has a R&D center for preclinical and clinical studies of drugs, and a licensed production of drugs for medical use.

Iphar has assembled a team of unique specialists in the field of synthesis, analytical chemistry, pharmaceutical development, preclinical and clinical research, the creation of normative and normative-technological documentation, drug registration, technology and organization of production, intellectual property protection, commercialization and attraction of investments, management in pharmaceutical business.

When implementing innovative drug development projects, we use our own scientific and technical base (laboratories, vivariums, pilot production), as well as technical, scientific and clinical capabilities of partners, including leading Russian universities and research institutes, as well as foreign organizations and specialists from Europe, the USA, Canada, Israel, China.

Over the past six years, more than 100 studies have been performed for Russian and foreign customers. Today, Iphar’s investment portfolio includes 18 projects of innovative drugs of varying degrees of readiness (antiplatelet agent, antiarrhythmic, analgesic, antidepressant, antiparkinsonian, anti-inflammatory, antiviral, anti-tumor, drug for the treatment of Alzheimer's disease, etc.).

Six of their own projects were supported by the Skolkovo Foundation, six by the Ministry of Industry and Trade of the Russian Federation and six by the Ministry of Education and Science of the Russian Federation as part of the implementation of the federal target program Pharma 2020.

Contact Information:

Address

634021, Tomsk, st. Elizarovih, 79/4

Mailing address

634034, Tomsk 34, PO Box 381

Phones

8 (3822) 24-87-13 Reception

8 (3822) 24-87-07 Reception

8 (3822) 24-87-21 Fax

E-mail: mail@iphar.ru